相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease
Osnat Itzhaki Ben Zadok et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
Patrice Marques et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Emily Punch et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)
Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
Sabina Ugovsek et al.
BIOMOLECULES (2022)
Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study
Thomas Metzner et al.
BIOMEDICINES (2022)
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Yoichi Morofuji et al.
PHARMACEUTICALS (2022)
PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction
Meidi Utami Puteri et al.
LIFE-BASEL (2022)
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
Stephen J. Nicholls et al.
JACC-CARDIOVASCULAR IMAGING (2022)
The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels
Tina Levstek et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2022)
LDL receptors, caveolae and cholesterol in endothelial dysfunction: oxLDLs accomplices or victims?
Francesca Luchetti et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
Zhiyong Qi et al.
CIRCULATION (2021)
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Piotr Peczek et al.
LIFE-BASEL (2021)
PCSK9 and atherosclerosis: Looking beyond LDL regulation
Rosetta Ragusa et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)
PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling
Valentina Scalise et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
Alvaro Petersen-Uribe et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease
Konstantin A. Krychtiuk et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2021)
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Aureli Luquero et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
PCSK9 Biology and Its Role in Atherothrombosis
Cristina Barale et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
Kausik K. Ray et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
Cristina Barale et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
Gregory G. Schwartz et al.
CIRCULATION (2020)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Nicholas A. Marston et al.
CIRCULATION (2020)
Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)
Lotte C. A. Stiekema et al.
EUROPEAN HEART JOURNAL (2020)
What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Barbara Cybulska et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2020)
Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
Thorsten M. Leucker et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
An Update on the Role of PCSK9 in Atherosclerosis
Ece Yurtseven et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy
Alessandro Di Minno et al.
THROMBOSIS RESEARCH (2020)
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
Adam J. Nelson et al.
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
Heart Disease and Stroke Statistics-2019 Update A Report From the American Heart Association
Emelia J. Benjamin et al.
CIRCULATION (2019)
Lipoprotein(a) is not associated with venous thromboembolism risk
Setor K. Kunutsor et al.
SCANDINAVIAN CARDIOVASCULAR JOURNAL (2019)
Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice
Thomas M. Stulnig et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
PCSK9 and inflammation: a review of experimental and clinical evidence
Amir Abbas Momtazi-Borojeni et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis[S]
Michael B. Boffa et al.
JOURNAL OF LIPID RESEARCH (2019)
PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers
Renate M. Hoogeveen et al.
JACC-CARDIOVASCULAR IMAGING (2019)
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
Lotte C. A. Stiekema et al.
EUROPEAN HEART JOURNAL (2019)
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
Francesco Paciullo et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
Aaron W. Aday et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2019)
Lipoprotein(a): A missing culprit in the management of athero-thrombosis?
Gianna Ferretti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
Angelos D. Karagiannis et al.
CURRENT ATHEROSCLEROSIS REPORTS (2018)
Improved endothelial function after short-term therapy with evolocumab
Guglielmo Maulucci et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
PCSK9 as a Positive Modulator of Platelet Activation
Marina Camera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
PCSK9 induces a pro-inflammatory response in macrophages
Chiara Ricci et al.
SCIENTIFIC REPORTS (2018)
No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia
Suzanne Schol-Gelok et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
Ye-Xuan Cao et al.
BMJ OPEN (2018)
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety
Eli M. Roth et al.
REVIEWS IN CARDIOVASCULAR MEDICINE (2018)
Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program
Robert M. Stoekenbroek et al.
FUTURE CARDIOLOGY (2018)
PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
Sophie J. Bernelot Moens et al.
EUROPEAN HEART JOURNAL (2017)
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
Eliano P. Nayarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
Daniele Pastori et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Claes Held et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review
Ahmad Hachem et al.
CURRENT CARDIOLOGY REVIEWS (2017)
The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke
Malgorzata Pawelczyk et al.
ARCHIVES OF MEDICAL SCIENCE (2017)
Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?
Michael B. Boffa et al.
JOURNAL OF LIPID RESEARCH (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
Sha Li et al.
ANNALS OF MEDICINE (2015)
Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
A. Sahebkar et al.
DIABETES OBESITY & METABOLISM (2015)
The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
Sha Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches
Kyoung-Ha Park et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia
Nabil A. Elshourbagy et al.
MEDICAL PRINCIPLES AND PRACTICE (2014)
Inflammation and coagulation in atherosclerosis
K. A. Krychtiuk et al.
HAMOSTASEOLOGIE (2013)
Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21 483 women
J. S. Danik et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis
Pia R. Kamstrup et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
The Thrombophilic Pattern of Different Clinical Manifestations of Venous Thromboembolism: A Survey of 443 Cases of Venous Thromboembolism
Elisa Grifoni et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2012)
The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients
Boguslawa Luzak et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
The Mysteries of Lipoprotein(a) and Cardiovascular Disease Revisited
Stefan Kiechl et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Effect of high dose statin therapy on platelet function; statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease
Ebru Tirnaksiz et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2009)
C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study
Jorgen Jeppesen et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort
HD Wu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Circulating endothelial progenitor cells, vascular function, and cardiovascular risk
JM Hill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Endothelial dysfunction - A marker of atherosclerotic risk
PO Bonetti et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism
R Marcucci et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia effects of statin therapy
F Cipollone et al.
CIRCULATION (2002)
Cardiovascular risk factors and venous thromboembolism incidence - The longitudinal investigation of thromboembolism etiology
AW Tsai et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease
T Heitzer et al.
CIRCULATION (2001)
分享论文
